Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EpCAM-specific CAR T Cells for EpCAM Positive Cancer
NCT03013712Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Chengdu Medical College
- Start
- Jan 2017
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in colon cancer, esophageal carcinoma, pancreatic cancer (PC) and 3 more, sponsored by The First Affiliated Hospital of Chengdu Medical College. Primary endpoint: Toxicity profile of the EpCAM targeted CAR T cells up to 24 months. Status: unknown.
02
Conditions
colon canceresophageal carcinomapancreatic cancer (PC)prostate cancer (PCa)gastric cancer (GC)
Beyond the preview
Go deeper on NCT03013712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013712.